RotaTeq (V260) + IPV

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

Conditions

Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

Trial Timeline

Aug 25, 2020 → May 8, 2021

NCT ID

NCT04481191

About RotaTeq (V260) + IPV

RotaTeq (V260) + IPV is a phase 3 stage product being developed by Merck for Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9. The current trial status is completed. This product is registered under clinical trial identifier NCT04481191. Target conditions include Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9.

What happened to similar drugs?

5 of 20 similar drugs in Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9 were approved

Approved (5) Terminated (0) Active (15)

🔄edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3

🔄DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3

🔄Esomeprazole + PlaceboAstraZenecaPhase 3

✅RaltegravirMerckApproved

🔄V501MerckPhase 3

🔄ZostavaxMerckPhase 3

🔄V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04481191	Phase 3	Completed	Aug 25, 2020	May 8, 2021	Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

Competing Products

20 competing products in Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

See all competitors

Product	Company	Stage	Hype Score
mRNA-1944	Moderna	Phase 1	0
Gam-COVID-Vac	Dr. Reddy's Laboratories	Phase 2/3	31
edoxaban + enoxaparin sodium	Daiichi Sankyo	Phase 3	40
Mifepristone	Eli Lilly	Phase 2	35
EXANTA	AstraZeneca	Phase 2	27
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	26
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	40
Esomeprazole + Placebo	AstraZeneca	Phase 3	40
PCV15	Merck	Pre-clinical	18
Raltegravir	Merck	Approved	43
V501	Merck	Phase 3	40
Zostavax	Merck	Phase 3	40
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920	Merck	Phase 3	40
Letermovir + Placebo	Merck	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
Enteric-coated mycophenolate sodium	Novartis	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
rMenB+OMV NZ	Novartis	Phase 3	40
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	40
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml	Novartis	Phase 3	44